NPI: 1649797507 · JEFFERSONTOWN, KY 40299 · Multi-Specialty Clinic/Center · NPI assigned 08/23/2017
Authorized official MCCORMAC, RUPERT controls 20+ related entities in our dataset. Read more
| Authorized Official | MCCORMAC, RUPERT (CHIEF EXECUTIVE OFFICER) |
| NPI Enumeration Date | 08/23/2017 |
Other providers sharing the same authorized official: MCCORMAC, RUPERT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 2,973 | $30K |
| 2019 | 172,276 | $914K |
| 2020 | 100,539 | $3.30M |
| 2021 | 39,674 | $2.20M |
| 2022 | 22,915 | $1.92M |
| 2023 | 42,510 | $2.73M |
| 2024 | 35,603 | $2.60M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 133,968 | 24,677 | $8.16M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 14,179 | 7,117 | $1.38M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 178,461 | 7,559 | $1.27M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 16,969 | 9,954 | $738K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 5,298 | 4,883 | $447K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | 5,438 | 4,275 | $320K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7,063 | 4,644 | $263K |
| 99408 | 25,361 | 1,102 | $240K | |
| H0033 | Oral medication administration, direct observation | 2,448 | 2,185 | $217K |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 1,982 | 1,058 | $196K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5,716 | 3,668 | $154K |
| 82075 | 5,061 | 4,471 | $110K | |
| 90832 | Psychotherapy, 30 minutes with patient | 6,110 | 2,761 | $82K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 281 | 246 | $44K |
| 80305 | 1,999 | 1,501 | $19K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 247 | 209 | $9K |
| 90791 | Psychiatric diagnostic evaluation | 249 | 205 | $8K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1,079 | 500 | $7K |
| 99441 | 2,339 | 808 | $4K | |
| 99406 | 719 | 593 | $4K | |
| 81025 | 345 | 301 | $2K | |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 184 | 66 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 593 | 294 | $1K |
| 36415 | Collection of venous blood by venipuncture | 99 | 97 | $505.24 |
| 90834 | Psychotherapy, 45 minutes with patient | 60 | 49 | $468.08 |
| 99215 | Prolong outpt/office vis | 71 | 43 | $395.96 |
| 86580 | 139 | 136 | $194.27 | |
| 96127 | 32 | 14 | $34.74 |